Biomea Fusion (NASDAQ:BMEA) Earns “Market Outperform” Rating from Citizens Jmp

Biomea Fusion (NASDAQ:BMEA)‘s stock had its “market outperform” rating reaffirmed by equities researchers at Citizens Jmp in a research report issued on Wednesday, Benzinga reports. They currently have a $7.00 price objective on the stock.

Several other brokerages also recently weighed in on BMEA. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Biomea Fusion in a report on Wednesday. Wall Street Zen raised shares of Biomea Fusion from a “sell” rating to a “hold” rating in a research note on Monday, October 5th. Brookline Capital Markets assumed coverage on shares of Biomea Fusion in a research report on Wednesday, October 7th. They set a “buy” rating for the company. Citigroup restated a “market outperform” rating on shares of Biomea Fusion in a research note on Wednesday, September 30th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Biomea Fusion in a research note on Monday, September 28th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.60.

Biomea Fusion Trading Down 33.8%

Shares of NASDAQ BMEA traded down $0.43 during midday trading on Wednesday, reaching $0.83. 11,672,629 shares of the company were exchanged, compared to its average volume of 1,475,090. Biomea Fusion has a 1 year low of $0.80 and a 1 year high of $2.24. The stock has a fifty day simple moving average of $1.53 and a 200 day simple moving average of $1.47. The stock has a market cap of $60.45 million, a P/E ratio of -2.88 and a beta of -0.28.

Biomea Fusion (NASDAQ:BMEA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.10. As a group, analysts forecast that Biomea Fusion will post -0.71 earnings per share for the current year.

Institutional Trading of Biomea Fusion

A number of institutional investors have recently modified their holdings of the business. Rathbones Group PLC purchased a new stake in shares of Biomea Fusion during the 1st quarter worth $57,000. ADAR1 Capital Management LLC acquired a new position in shares of Biomea Fusion during the 2nd quarter worth $64,000. GSA Capital Partners LLP acquired a new position in shares of Biomea Fusion during the 2nd quarter worth $318,000. BlackRock Inc. purchased a new position in shares of Biomea Fusion in the 2nd quarter valued at about $1,052,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Biomea Fusion by 174.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock valued at $2,009,000 after purchasing an additional 834,179 shares in the last quarter. 96.72% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Biomea Fusion

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: Analyst support remains bullish. Citizens JMP reaffirmed its “Market Outperform” rating and assigned a $7 price target, while HC Wainwright reaffirmed its “Buy” rating with a $4 target. These targets imply substantial potential upside from recent trading levels, but they remain analyst estimates rather than guaranteed outcomes.
• Positive Sentiment: BMF-650 demonstrated early clinical activity. Biomea reported consistent weight reduction across five multiple-ascending-dose cohorts over four weeks, with patients reaching doses as high as 400 mg once daily after a single one-week titration period. The company also characterized tolerability as encouraging. Biomea Fusion Announces Phase 1 Results for BMF-650
• Neutral Sentiment: Management highlighted the potential to separate gastrointestinal side effects from weight loss. The accompanying discussion focused on BMF-650’s potential differentiation from existing GLP-1 therapies, but this remains an early hypothesis requiring additional clinical validation. BMF-650 Phase I Topline Results Transcript
• Negative Sentiment: The shares fell following the Phase 1 readout. Investors may have viewed the four-week, early-stage dataset as insufficient to establish BMF-650’s durability, comparative efficacy, or long-term safety. The stock is also trading near its 52-week low, reflecting substantial skepticism despite the bullish analyst targets. Biomea Reports Phase 1 Weight-Loss Data for BMF-650

Biomea Fusion Company Profile

Biomea Fusion, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for serious diseases with significant unmet medical needs. The company’s research platform is centered on covalent chemistry, an approach designed to create potentially durable interactions between medicines and their biological targets.

Biomea’s lead investigational product is icovamenib, formerly known as BMF-219, an oral covalent menin inhibitor. The company has evaluated icovamenib in oncology indications, including certain blood cancers, and is also investigating its potential in metabolic diseases such as diabetes.